InFlectis BioScience is a private drug discovery company aiming at targeting.
Business Model:
Revenue: $0
Employees: 1-10
Address:
City: Nantes
State: Pays de la Loire
Zip:
Country: France
InFlectis BioScience is leveraging its leading expertise in the cellular defense system against misfolded proteins and drug discovery to identify and develop small molecules which modulate key proteins involved in misfolded protein disorders. Endoplasmic Reticulum (ER) proteostasis is vital for cellular function and cell survival. Many different perturbations can alter the folding capacity of the ER and may cause accumulation of unfolded or misfolded proteins inside the ER, a cellular condition referred to as ER stress. To safeguard proteostasis, the mammalian ER has a complex machinery to maintain the integrity of cells. This adaptive programme is called the unfolded protein response (UPR).
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 6/2016 | Series A | 4 | $6.8M |
Crédit Mutuel Innovation GO CAPITAL Participations Besancon Remiges Ventures Crédit Mutuel Innovation GO CAPITAL Participations Besancon Remiges Ventures |
1/2015 | Seed Round | 1 | $2.1M |
GO CAPITAL GO CAPITAL |
6/2016 | Series A | 4 | $6.8M |
Crédit Mutuel Innovation GO CAPITAL Participations Besancon Remiges Ventures Crédit Mutuel Innovation GO CAPITAL Participations Besancon Remiges Ventures |
1/2015 | Seed Round | 1 | $2.1M |
GO CAPITAL GO CAPITAL |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|